iShares Core S&P Small-Cap ETF, formerly iShares S&P SmallCap 600 Index Fund, seeks investment results that correspond generally to the price and yield performance of the Standard & Poor's SmallCap 600 Index (the Index). The Index measures the performance of publicly traded securities in the small-capitalization sector of the United States equity market. The Index serves as the underlying index for the S&P 600/Citigroup Growth and Value Index series. The component stocks are weighted according to the total float-adjusted market value of their outstanding shares. The component stocks in the Index have a market capitalization between $300 million and $1 billion (which may fluctuate depending on the overall level of the equity markets), and are selected for liquidity and industry group representation. The Index is adjusted to reflect changes in capitalization resulting from mergers, acquisition, stock rights, substitutions and other capital events.
Basic Details
Issuer iShares
Fund NameiShares Core S&P Small-Cap ETF
Tax ClassificationRegulated Investment Company
SymbolNYSEARCA:IJR
Inception Date5/22/2000
Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason
Phone+1-800-4742737
Fund Focus
Asset ClassEquity
BenchmarkS&P SmallCap 600 Index
CategorySize and Style
FocusSmall Cap
Development LevelDeveloped Markets
RegionNorth America
Fund Statistics
Assets Under Management$48.73 billion
Average Daily Volume$2.74 million
Discount/Premium-0.02%
ETF Expenses
Management Fee0.07%
Other Expenses0.00%
Total Expenses0.07%
Fee Waiver0.00%
Net Expenses0.07%
Administrator, Advisor and Custodian
AdministratorState Street Bank and Trust Company
AdvisorBlackRock Fund Advisors
CustodianState Street Bank and Trust Company
DistributorBlackRock Investments, LLC
Transfer AgentState Street Bank and Trust Company
Trustee
Lead Market MakerPundion
(Ad)
If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval.
